However, this method has problems such as high staining costs, tumor heterogeneity, and subjective differences among pathologists. Therefore, the application of deep learning models to segment and ...

Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

Whenever a sink overflows, the flooding is usually caused by a blockage that has built up in the drains. Similarly, as we age ...

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

Tecentriq, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50 ...

CTX-10726 is a tetravalent PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass. CTX-10726 is designed to synergistically deliver VEGF-A blockade and checkpoint inhibition, ...

Tumors with a high level of TILs also have high expression of PD-L1, "but PD-L1-negative tumors ... nodes followed by the licensing of lymphatic cells that circulate back to the area of ...

The Phase 1/2a clinical trial enrolled patients with advanced, refractory cancers unresponsive to prior anti-PD-1 or anti-PD-L1 therapies ... sequential tumor biopsies and immune cell analysis.

CAR T cell therapy revolutionizes oncology by using engineered T cells to target and eliminate cancer cells, improving ...